



OPEN ACCESS

EDITED BY

Shengxi Chen,
Arizona State University, United States

REVIEWED BY

Sowmya Ramesh,
Johns Hopkins University, United States
Parmanand Malvi,
University of Alabama at Birmingham,
United States

*CORRESPONDENCE

Muzafar A. Macha,
✉ muzafar.macha@iust.ac.in,
✉ muzafar.aiiims@gmail.com
Ajaz A. Bhat,
✉ abhat@sidra.org

RECEIVED 29 April 2024

ACCEPTED 30 July 2024

PUBLISHED 21 August 2024

CITATION

Khurshid S, Usmani S, Ali R, Hamid S,
Masoodi T, Sadida HQ, Ahmed I, Khan MS,
Abeer I, Albalawi IA, Bedaiwi RI, Mir R,
Al-Shabeeb Akil AS, Bhat AA and Macha MA
(2024) Integrating network analysis with
differential expression to uncover therapeutic
and prognostic biomarkers in esophageal
squamous cell carcinoma.
Front. Mol. Biosci. 11:1425422.
doi: 10.3389/fmolb.2024.1425422

COPYRIGHT

© 2024 Khurshid, Usmani, Ali, Hamid,
Masoodi, Sadida, Ahmed, Khan, Abeer,
Albalawi, Bedaiwi, Mir, Al-Shabeeb Akil, Bhat
and Macha. This is an open-access article
distributed under the terms of the Creative
Commons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Integrating network analysis with differential expression to uncover therapeutic and prognostic biomarkers in esophageal squamous cell carcinoma

Sana Khurshid¹, Shahabuddin Usmani², Raiyan Ali³,
Saira Hamid¹, Tariq Masoodi⁴, Hana Q. Sadida², Ikhlak Ahmed²,
Mohd Shahnawaz Khan⁵, Inara Abeer⁶,
Ibrahim Altedlawi Albalawi⁷, Ruqaiah I. Bedaiwi⁸, Rashid Mir⁸,
Ammira S. Al-Shabeeb Akil², Ajaz A. Bhat^{2*} and
Muzafar A. Macha^{1*}

¹Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, India, ²Department of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar, ³Council of Scientific and Industrial Research-Institute of Genomics and Integrative Biology, Delhi, India, ⁴Human Immunology Department, Research Branch, Sidra Medicine, Doha, Qatar, ⁵Department of Biochemistry, College of Sciences, King Saud University, Riyadh, Saudi Arabia, ⁶Department of Pathology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India, ⁷Department of Surgical Oncology, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia, ⁸Faculty of Applied Medical Sciences, Medical Laboratory Technology, University of Tabuk, Tabuk, Saudi Arabia

Introduction: Esophageal squamous cell carcinoma (ESCC) accounts for over 90% of all esophageal tumors. However, the molecular mechanism underlying ESCC development and prognosis remains unclear, and there are still no effective molecular biomarkers for diagnosing or predicting the clinical outcome of patients with ESCC. Here, we used bioinformatics analysis to identify potential biomarkers and therapeutic targets for ESCC.

Methodology: Differentially expressed genes (DEGs) between ESCC and normal esophageal tissue samples were obtained by comprehensively analyzing publicly available RNA-seq datasets from the TCGA and GTEx. Gene Ontology (GO) annotation and Reactome pathway analysis identified the biological roles of the DEGs. Moreover, the Cytoscape 3.10.1 platform and subsidiary tools such as CytoHubba were used to visualize the DEGs' protein-protein interaction (PPI) network and identify hub genes. Furthermore our results are validated by using Single-cell RNA analysis. Results: Identification of 2524 genes exhibiting altered expression enriched in pathways including keratinization, epidermal cell differentiation, G alpha(s) signaling events, and biological process of cell proliferation and division, extracellular matrix (ECM) disassembly, and muscle function. Moreover, upregulation of hallmarks E2F targets, G2M checkpoints, and TNF signaling. CytoHubba revealed 20 hub genes that had a valuable influence on the progression of ESCC in these patients. Among these, the high expression levels of four genes, CDK1, MAD2L1, PLK1, and TOP2A, were